#begin document (nw/wsj/09/wsj_0932); part 000
nw/wsj/09/wsj_0932   0    0            The    DT  (TOP(S(NP(NP*          -    -   -   -   *             *             *        (ARG1*             *   -
nw/wsj/09/wsj_0932   0    1         amount    NN              *)         -    -   -   -   *             *             *             *             *   -
nw/wsj/09/wsj_0932   0    2             of    IN           (PP*          -    -   -   -   *             *             *             *             *   -
nw/wsj/09/wsj_0932   0    3          blood    NN        (NP(NP*)         -    -   -   -   *        (ARG1*)       (ARG1*)            *             *   -
nw/wsj/09/wsj_0932   0    4       surgical    JJ    (SBAR(S(NP*          -    -   -   -   *        (ARG0*        (ARG0*             *             *   -
nw/wsj/09/wsj_0932   0    5       patients   NNS              *)         -    -   -   -   *             *)            *)            *             *   -
nw/wsj/09/wsj_0932   0    6            can    MD           (VP*          -    -   -   -   *    (ARGM-MOD*)   (ARGM-MOD*)            *             *   -
nw/wsj/09/wsj_0932   0    7         donate    VB           (VP*      donate  01   1   -   *           (V*)            *             *             *   -
nw/wsj/09/wsj_0932   0    8            and    CC              *          -    -   -   -   *             *             *             *             *   -
nw/wsj/09/wsj_0932   0    9          store    VB              *       store  01   1   -   *             *           (V*)            *             *   -
nw/wsj/09/wsj_0932   0   10         before    IN           (PP*          -    -   -   -   *    (ARGM-TMP*    (ARGM-TMP*             *             *   -
nw/wsj/09/wsj_0932   0   11        surgery    NN   (NP*)))))))))         -    -   -   -   *             *)            *)            *)            *   -
nw/wsj/09/wsj_0932   0   12            can    MD           (VP*          -    -   -   -   *             *             *    (ARGM-MOD*)            *   -
nw/wsj/09/wsj_0932   0   13             be    VB           (VP*          -    -   -   -   *             *             *             *             *   -
nw/wsj/09/wsj_0932   0   14      increased   VBN           (VP*    increase  01   1   -   *             *             *           (V*)            *   -
nw/wsj/09/wsj_0932   0   15             by    IN           (PP*          -    -   -   -   *             *             *        (ARG0*             *   -
nw/wsj/09/wsj_0932   0   16            the    DT        (NP(NP*          -    -   -   -   *             *             *             *             *   -
nw/wsj/09/wsj_0932   0   17            new    JJ              *          -    -   -   -   *             *             *             *             *   -
nw/wsj/09/wsj_0932   0   18    genetically    RB         (ADJP*          -    -   -   -   *             *             *             *    (ARGM-MNR*)  -
nw/wsj/09/wsj_0932   0   19     engineered   VBN              *)   engineer  01   -   -   *             *             *             *           (V*)  -
nw/wsj/09/wsj_0932   0   20           drug    NN              *)         -    -   -   -   *             *             *             *        (ARG1*)  -
nw/wsj/09/wsj_0932   0   21              ,     ,              *          -    -   -   -   *             *             *             *             *   -
nw/wsj/09/wsj_0932   0   22            EPO   NNP      (NP*))))))         -    -   -   -   *             *             *             *)            *   -
nw/wsj/09/wsj_0932   0   23              .     .             *))         -    -   -   -   *             *             *             *             *   -

nw/wsj/09/wsj_0932   0    0               EPO   NNP   (TOP(S(NP(NP*)          -    -   -   -   *   (ARG1*            *        *   -
nw/wsj/09/wsj_0932   0    1                 ,     ,               *           -    -   -   -   *        *            *        *   -
nw/wsj/09/wsj_0932   0    2                or    CC               *           -    -   -   -   *        *            *        *   -
nw/wsj/09/wsj_0932   0    3    erythropoietin    NN            (NP*)          -    -   -   -   *        *            *        *   -
nw/wsj/09/wsj_0932   0    4                 ,     ,               *)          -    -   -   -   *        *)           *        *   -
nw/wsj/09/wsj_0932   0    5                is   VBZ            (VP*           be  01   -   -   *      (V*)           *        *   -
nw/wsj/09/wsj_0932   0    6                 a    DT         (NP(NP*           -    -   -   -   *   (ARG2*       (ARG1*        *   -
nw/wsj/09/wsj_0932   0    7           protein    NN               *)          -    -   -   -   *        *            *)       *   -
nw/wsj/09/wsj_0932   0    8               the    DT     (SBAR(S(NP*           -    -   -   -   *        *       (ARG0*   (ARG0*   -
nw/wsj/09/wsj_0932   0    9             human    JJ               *           -    -   -   -   *        *            *        *   -
nw/wsj/09/wsj_0932   0   10              body    NN               *)          -    -   -   -   *        *            *)       *)  -
nw/wsj/09/wsj_0932   0   11             makes   VBZ            (VP*         make  01   -   -   *        *          (V*)       *   -
nw/wsj/09/wsj_0932   0   12                to    TO          (S(VP*           -    -   -   -   *        *   (ARGM-PRP*        *   -
nw/wsj/09/wsj_0932   0   13         stimulate    VB            (VP*    stimulate  01   1   -   *        *            *      (V*)  -
nw/wsj/09/wsj_0932   0   14               the    DT         (NP(NP*           -    -   -   -   *        *            *   (ARG1*   -
nw/wsj/09/wsj_0932   0   15            growth    NN               *)          -    -   -   -   *        *            *        *   -
nw/wsj/09/wsj_0932   0   16                of    IN            (PP*           -    -   -   -   *        *            *        *   -
nw/wsj/09/wsj_0932   0   17               red    JJ            (NP*           -    -   -   -   *        *            *        *   -
nw/wsj/09/wsj_0932   0   18             blood    NN               *           -    -   -   -   *        *            *        *   -
nw/wsj/09/wsj_0932   0   19             cells   NNS     *)))))))))))          -    -   -   -   *        *)           *)       *)  -
nw/wsj/09/wsj_0932   0   20                 .     .              *))          -    -   -   -   *        *            *        *   -

nw/wsj/09/wsj_0932   0    0                  A    DT  (TOP(S(NP(NP(NP*          -    -   -   -       *             *   (ARG1*        (ARG1*   -
nw/wsj/09/wsj_0932   0    1        genetically    RB            (ADJP*          -    -   -   -       *    (ARGM-MNR*)       *             *   -
nw/wsj/09/wsj_0932   0    2         engineered   VBN                 *)   engineer  01   -   -       *           (V*)       *             *   -
nw/wsj/09/wsj_0932   0    3            version    NN                 *)         -    -   -   -       *        (ARG1*)       *             *   -
nw/wsj/09/wsj_0932   0    4                 of    IN              (PP*          -    -   -   -       *             *        *             *   -
nw/wsj/09/wsj_0932   0    5                the    DT              (NP*          -    -   -   -       *             *        *             *   -
nw/wsj/09/wsj_0932   0    6              human    JJ                 *          -    -   -   -       *             *        *             *   -
nw/wsj/09/wsj_0932   0    7            protein    NN               *)))         -    -   -   -       *             *        *)            *   -
nw/wsj/09/wsj_0932   0    8          developed   VBN              (VP*     develop  02   -   -       *             *      (V*)            *   -
nw/wsj/09/wsj_0932   0    9                 by    IN              (PP*          -    -   -   -       *             *   (ARG0*             *   -
nw/wsj/09/wsj_0932   0   10              Amgen   NNP           (NP(NP*          -    -   -   -   (ORG*             *        *             *   -
nw/wsj/09/wsj_0932   0   11              Corp.   NNP                 *)         -    -   -   -       *)            *        *             *   -
nw/wsj/09/wsj_0932   0   12                 of    IN              (PP*          -    -   -   -       *             *        *             *   -
nw/wsj/09/wsj_0932   0   13           Thousand   NNP           (NP(NP*          -    -   -   -   (GPE*             *        *             *   -
nw/wsj/09/wsj_0932   0   14               Oaks   NNP                 *)         -    -   -   -       *)            *        *             *   -
nw/wsj/09/wsj_0932   0   15                  ,     ,                 *          -    -   -   -       *             *        *             *   -
nw/wsj/09/wsj_0932   0   16             Calif.   NNP              (NP*)         -    -   -   -    (GPE)            *        *             *   -
nw/wsj/09/wsj_0932   0   17                  ,     ,            *))))))         -    -   -   -       *             *        *)            *)  -
nw/wsj/09/wsj_0932   0   18           recently    RB            (ADVP*)         -    -   -   -       *             *        *    (ARGM-TMP*)  -
nw/wsj/09/wsj_0932   0   19                has   VBZ              (VP*          -    -   -   -       *             *        *             *   -
nw/wsj/09/wsj_0932   0   20               been   VBN              (VP*          -    -   -   -       *             *        *             *   -
nw/wsj/09/wsj_0932   0   21           marketed   VBN              (VP*      market  01   1   -       *             *        *           (V*)  -
nw/wsj/09/wsj_0932   0   22                 by    IN              (PP*          -    -   -   -       *             *        *        (ARG0*   -
nw/wsj/09/wsj_0932   0   23                the    DT           (NP(NP*          -    -   -   -       *             *        *             *   -
nw/wsj/09/wsj_0932   0   24              Ortho   NNP             (NML*          -    -   -   -   (ORG*             *        *             *   -
nw/wsj/09/wsj_0932   0   25    Pharmaceuticals   NNP                 *)         -    -   -   -       *)            *        *             *   -
nw/wsj/09/wsj_0932   0   26           division    NN                 *)         -    -   -   -       *             *        *             *   -
nw/wsj/09/wsj_0932   0   27                 of    IN              (PP*          -    -   -   -       *             *        *             *   -
nw/wsj/09/wsj_0932   0   28            Johnson   NNP              (NP*          -    -   -   -   (ORG*             *        *             *   -
nw/wsj/09/wsj_0932   0   29                  &    CC                 *          -    -   -   -       *             *        *             *   -
nw/wsj/09/wsj_0932   0   30            Johnson   NNP           *)))))))         -    -   -   -       *)            *        *             *)  -
nw/wsj/09/wsj_0932   0   31                  .     .                *))         -    -   -   -       *             *        *             *   -

nw/wsj/09/wsj_0932   0    0            A    DT  (TOP(S(NP(NP*         -    -   -   -       *         *   (ARG1*   -
nw/wsj/09/wsj_0932   0    1    competing   VBG              *    compete  01   1   -       *       (V*)       *   -
nw/wsj/09/wsj_0932   0    2      version    NN              *)        -    -   -   -       *    (ARG0*)       *   -
nw/wsj/09/wsj_0932   0    3           of    IN           (PP*         -    -   -   -       *         *        *   -
nw/wsj/09/wsj_0932   0    4          EPO   NNP         (NP*)))        -    -   -   -       *         *        *)  -
nw/wsj/09/wsj_0932   0    5           is   VBZ           (VP*         -    -   -   -       *         *        *   -
nw/wsj/09/wsj_0932   0    6        being   VBG           (VP*         -    -   -   -       *         *        *   -
nw/wsj/09/wsj_0932   0    7    developed   VBN           (VP*    develop  02   -   -       *         *      (V*)  -
nw/wsj/09/wsj_0932   0    8           by    IN           (PP*         -    -   -   -       *         *   (ARG0*   -
nw/wsj/09/wsj_0932   0    9     Genetics   NNP        (NP(NP*         -    -   -   -   (ORG*         *        *   -
nw/wsj/09/wsj_0932   0   10    Institute   NNP              *         -    -   -   -       *         *        *   -
nw/wsj/09/wsj_0932   0   11         Inc.   NNP              *)        -    -   -   -       *)        *        *   -
nw/wsj/09/wsj_0932   0   12           in    IN           (PP*         -    -   -   -       *         *        *   -
nw/wsj/09/wsj_0932   0   13    Cambridge   NNP        (NP(NP*)        -    -   -   -    (GPE)        *        *   -
nw/wsj/09/wsj_0932   0   14            ,     ,              *         -    -   -   -       *         *        *   -
nw/wsj/09/wsj_0932   0   15         Mass   NNP    (NP*))))))))        -    -   -   -    (GPE)        *        *)  -
nw/wsj/09/wsj_0932   0   16            .     .             *))        -    -   -   -       *         *        *   -

nw/wsj/09/wsj_0932   0   0          The    DT   (TOP(S(NP*       -    -   -   -   *        (ARG1*    (ARG3*   -
nw/wsj/09/wsj_0932   0   1         drug    NN            *)      -    -   -   -   *             *)        *)  -
nw/wsj/09/wsj_0932   0   2           is   VBZ         (VP*       -    -   -   -   *             *         *   -
nw/wsj/09/wsj_0932   0   3        being   VBG         (VP*       -    -   -   -   *             *         *   -
nw/wsj/09/wsj_0932   0   4         used   VBN         (VP*      use  01   -   -   *           (V*)        *   -
nw/wsj/09/wsj_0932   0   5    primarily    RB       (ADVP*)      -    -   -   -   *    (ARGM-ADV*)        *   -
nw/wsj/09/wsj_0932   0   6           to    TO       (S(VP*       -    -   -   -   *        (ARG2*         *   -
nw/wsj/09/wsj_0932   0   7        treat    VB         (VP*    treat  03   -   -   *             *       (V*)  -
nw/wsj/09/wsj_0932   0   8      anemias   NNS   (NP*)))))))      -    -   -   -   *             *)   (ARG2*)  -
nw/wsj/09/wsj_0932   0   9            .     .           *))      -    -   -   -   *             *         *   -

nw/wsj/09/wsj_0932   0    0             A     DT    (TOP(S(NP(NP*         -    -   -   -            *       (ARG1*   (ARG2*        *           *         *   -
nw/wsj/09/wsj_0932   0    1           new     JJ                *         -    -   -   -            *            *        *        *           *         *   -
nw/wsj/09/wsj_0932   0    2    experiment     NN                *)        -    -   -   -            *            *)       *        *           *         *   -
nw/wsj/09/wsj_0932   0    3             ,      ,                *         -    -   -   -            *            *        *        *           *         *   -
nw/wsj/09/wsj_0932   0    4      reported    VBN             (VP*     report  01   -   -            *          (V*)       *        *           *         *   -
nw/wsj/09/wsj_0932   0    5            in     IN             (PP*         -    -   -   -            *   (ARGM-LOC*        *        *           *         *   -
nw/wsj/09/wsj_0932   0    6          this     DT       (NP(NP(NP*         -    -   -   -            *            *        *        *           *         *   -
nw/wsj/09/wsj_0932   0    7          week     NN                *         -    -   -   -        (DATE)           *        *        *           *         *   -
nw/wsj/09/wsj_0932   0    8            's    POS                *)        -    -   -   -            *            *        *        *           *         *   -
nw/wsj/09/wsj_0932   0    9           New    NNP            (NML*         -    -   -   -        (ORG*            *        *        *           *         *   -
nw/wsj/09/wsj_0932   0   10       England    NNP                *)        -    -   -   -            *            *        *        *           *         *   -
nw/wsj/09/wsj_0932   0   11       Journal    NNP                *)        -    -   -   -            *            *        *        *           *         *   -
nw/wsj/09/wsj_0932   0   12            of     IN             (PP*         -    -   -   -            *            *        *        *           *         *   -
nw/wsj/09/wsj_0932   0   13      Medicine    NNP         (NP*)))))        -    -   -   -            *)           *)       *        *           *         *   -
nw/wsj/09/wsj_0932   0   14             ,      ,                *)        -    -   -   -            *            *        *)       *           *         *   -
nw/wsj/09/wsj_0932   0   15      involved    VBD             (VP*    involve  01   -   -            *            *      (V*)       *           *         *   -
nw/wsj/09/wsj_0932   0   16        giving    VBG           (S(VP*       give  01   -   -            *            *   (ARG1*      (V*)          *         *   -
nw/wsj/09/wsj_0932   0   17    injections    NNS          (NP(NP*)        -    -   -   -            *            *        *   (ARG1*           *         *   -
nw/wsj/09/wsj_0932   0   18            of     IN             (PP*         -    -   -   -            *            *        *        *           *         *   -
nw/wsj/09/wsj_0932   0   19         Amgen    NNP          (NP(NP*         -    -   -   -         (ORG)           *        *        *           *         *   -
nw/wsj/09/wsj_0932   0   20            's    POS                *)        -    -   -   -            *            *        *        *           *         *   -
nw/wsj/09/wsj_0932   0   21           EPO    NNP              *)))        -    -   -   -            *            *        *        *)          *         *   -
nw/wsj/09/wsj_0932   0   22            to     IN             (PP*         -    -   -   -            *            *        *   (ARG2*           *         *   -
nw/wsj/09/wsj_0932   0   23           23      CD          (NP(NP*         -    -   -   -    (CARDINAL)           *        *        *      (ARG0*         *   -
nw/wsj/09/wsj_0932   0   24      patients    NNS                *)        -    -   -   -            *            *        *        *           *)        *   -
nw/wsj/09/wsj_0932   0   25           who     WP      (SBAR(WHNP*)        -    -   -   -            *            *        *        *    (R-ARG0*)   (ARG0*)  -
nw/wsj/09/wsj_0932   0   26        wanted    VBD           (S(VP*       want  01   -   -            *            *        *        *         (V*)        *   -
nw/wsj/09/wsj_0932   0   27            to     TO           (S(VP*         -    -   -   -            *            *        *        *      (ARG1*         *   -
nw/wsj/09/wsj_0932   0   28         store     VB             (VP*      store  01   1   -            *            *        *        *           *       (V*)  -
nw/wsj/09/wsj_0932   0   29         units    NNS          (NP(NP*)        -    -   -   -            *            *        *        *           *    (ARG1*   -
nw/wsj/09/wsj_0932   0   30            of     IN             (PP*         -    -   -   -            *            *        *        *           *         *   -
nw/wsj/09/wsj_0932   0   31         their   PRP$             (NP*         -    -   -   -            *            *        *        *           *         *   -
nw/wsj/09/wsj_0932   0   32           own     JJ                *         -    -   -   -            *            *        *        *           *         *   -
nw/wsj/09/wsj_0932   0   33         blood     NN   *))))))))))))))        -    -   -   -            *            *        *)       *)          *)        *)  -
nw/wsj/09/wsj_0932   0   34             .      .               *))        -    -   -   -            *            *        *        *           *         *   -

nw/wsj/09/wsj_0932   0    0           The     DT  (TOP(S(NP*          -    -   -   -        *     (ARG1*       (ARG0*         *   -
nw/wsj/09/wsj_0932   0    1      patients    NNS           *)         -    -   -   -        *          *)           *)        *   -
nw/wsj/09/wsj_0932   0    2         began    VBD        (VP*       begin  01   -   -        *        (V*)           *         *   -
nw/wsj/09/wsj_0932   0    3     receiving    VBG      (S(VP*     receive  01   -   -        *   (C-ARG1*          (V*)        *   -
nw/wsj/09/wsj_0932   0    4           EPO    NNP        (NP*          -    -   -   -        *          *       (ARG1*         *   -
nw/wsj/09/wsj_0932   0    5    injections    NNS           *)         -    -   -   -        *          *            *)        *   -
nw/wsj/09/wsj_0932   0    6         about     IN  (PP(NP(QP*          -    -   -   -   (DATE*          *   (ARGM-TMP*         *   -
nw/wsj/09/wsj_0932   0    7             a     DT           *)         -    -   -   -        *          *            *         *   -
nw/wsj/09/wsj_0932   0    8         month     NN           *)         -    -   -   -        *)         *            *         *   -
nw/wsj/09/wsj_0932   0    9        before     IN           *          -    -   -   -        *          *            *         *   -
nw/wsj/09/wsj_0932   0   10         their   PRP$        (NP*          -    -   -   -        *          *            *         *   -
nw/wsj/09/wsj_0932   0   11     scheduled    VBN           *    schedule  01   -   -        *          *            *       (V*)  -
nw/wsj/09/wsj_0932   0   12       surgery     NN       *)))))         -    -   -   -        *          *)           *)   (ARG1*)  -
nw/wsj/09/wsj_0932   0   13             .      .          *))         -    -   -   -        *          *            *         *   -

nw/wsj/09/wsj_0932   0    0         They   PRP   (TOP(S(NP*)        -    -   -   -            *        (ARG0*)      (ARG0*)      (ARG0*)  -
nw/wsj/09/wsj_0932   0    1         then    RB       (ADVP*)        -    -   -   -            *    (ARGM-TMP*)           *            *   -
nw/wsj/09/wsj_0932   0    2        began   VBD         (VP*      begin  01   -   -            *           (V*)           *            *   -
nw/wsj/09/wsj_0932   0    3     donating   VBG       (S(VP*     donate  01   1   -            *        (ARG1*          (V*)           *   -
nw/wsj/09/wsj_0932   0    4        blood    NN         (NP*)        -    -   -   -            *             *       (ARG1*)           *   -
nw/wsj/09/wsj_0932   0    5        twice   PDT         (NP*         -    -   -   -    (CARDINAL)            *   (ARGM-TMP*            *   -
nw/wsj/09/wsj_0932   0    6            a    DT            *         -    -   -   -            *             *            *            *   -
nw/wsj/09/wsj_0932   0    7         week    NN            *)        -    -   -   -            *             *            *)           *   -
nw/wsj/09/wsj_0932   0    8            ,     ,            *         -    -   -   -            *             *            *            *   -
nw/wsj/09/wsj_0932   0    9    receiving   VBG       (S(VP*    receive  01   -   -            *             *   (ARGM-ADV*          (V*)  -
nw/wsj/09/wsj_0932   0   10           an    DT         (NP*         -    -   -   -            *             *            *       (ARG1*   -
nw/wsj/09/wsj_0932   0   11          EPO   NNP            *         -    -   -   -            *             *            *            *   -
nw/wsj/09/wsj_0932   0   12    injection    NN            *)        -    -   -   -            *             *            *            *)  -
nw/wsj/09/wsj_0932   0   13         each    DT         (NP*         -    -   -   -            *             *            *   (ARGM-TMP*   -
nw/wsj/09/wsj_0932   0   14         time    NN       *))))))        -    -   -   -            *             *)           *)           *)  -
nw/wsj/09/wsj_0932   0   15            .     .           *))        -    -   -   -            *             *            *            *   -

nw/wsj/09/wsj_0932   0    0           If    IN  (TOP(S(SBAR*          -    -   -   -   *         *    (ARGM-ADV*   -
nw/wsj/09/wsj_0932   0    1        tests   NNS        (S(NP*)         -    -   -   -   *    (ARG0*)            *   -
nw/wsj/09/wsj_0932   0    2    indicated   VBD          (VP*    indicate  01   -   -   *       (V*)            *   -
nw/wsj/09/wsj_0932   0    3            a    DT       (NP(NP*          -    -   -   -   *    (ARG1*             *   -
nw/wsj/09/wsj_0932   0    4          low    JJ             *          -    -   -   -   *         *             *   -
nw/wsj/09/wsj_0932   0    5       number    NN             *)         -    -   -   -   *         *             *   -
nw/wsj/09/wsj_0932   0    6           of    IN          (PP*          -    -   -   -   *         *             *   -
nw/wsj/09/wsj_0932   0    7          red    JJ          (NP*          -    -   -   -   *         *             *   -
nw/wsj/09/wsj_0932   0    8        cells   NNS        *))))))         -    -   -   -   *         *)            *)  -
nw/wsj/09/wsj_0932   0    9            ,     ,             *          -    -   -   -   *         *             *   -
nw/wsj/09/wsj_0932   0   10        blood    NN          (NP*)         -    -   -   -   *         *        (ARG1*)  -
nw/wsj/09/wsj_0932   0   11          was   VBD          (VP*          -    -   -   -   *         *             *   -
nw/wsj/09/wsj_0932   0   12          n't    RB             *          -    -   -   -   *         *    (ARGM-NEG*)  -
nw/wsj/09/wsj_0932   0   13        taken   VBN         (VP*))       take  01   -   -   *         *           (V*)  -
nw/wsj/09/wsj_0932   0   14            .     .            *))         -    -   -   -   *         *             *   -

nw/wsj/09/wsj_0932   0    0          The     DT      (TOP(S(NP*         -    -   -   -            *       (ARG0*        *           *   -
nw/wsj/09/wsj_0932   0    1          EPO    NNP          (ADJP*         -    -   -   -            *            *        *           *   -
nw/wsj/09/wsj_0932   0    2           -    HYPH               *         -    -   -   -            *            *        *           *   -
nw/wsj/09/wsj_0932   0    3      treated    VBN               *)        -    -   -   -            *            *        *           *   -
nw/wsj/09/wsj_0932   0    4     patients    NNS               *)        -    -   -   -            *            *)       *           *   -
nw/wsj/09/wsj_0932   0    5      donated    VBD            (VP*     donate  01   1   -            *          (V*)       *           *   -
nw/wsj/09/wsj_0932   0    6           an     DT         (NP(NP*         -    -   -   -            *       (ARG1*        *           *   -
nw/wsj/09/wsj_0932   0    7      average     NN               *)        -    -   -   -            *            *        *           *   -
nw/wsj/09/wsj_0932   0    8           of     IN            (PP*         -    -   -   -            *            *        *           *   -
nw/wsj/09/wsj_0932   0    9         5.4      CD         (NP(NP*         -    -   -   -    (CARDINAL)           *        *           *   -
nw/wsj/09/wsj_0932   0   10        units    NNS               *)        -    -   -   -            *            *        *           *   -
nw/wsj/09/wsj_0932   0   11           of     IN            (PP*         -    -   -   -            *            *        *           *   -
nw/wsj/09/wsj_0932   0   12        blood     NN         (NP*))))        -    -   -   -            *            *        *           *   -
nw/wsj/09/wsj_0932   0   13         each     DT           (NP*))        -    -   -   -            *            *)       *           *   -
nw/wsj/09/wsj_0932   0   14     compared    VBN            (PP*         -    -   -   -            *   (ARGM-ADV*        *           *   -
nw/wsj/09/wsj_0932   0   15         with     IN            (PP*         -    -   -   -            *            *        *           *   -
nw/wsj/09/wsj_0932   0   16         only     RB      (NP(NP(QP*         -    -   -   -   (CARDINAL*            *   (ARG1*           *   -
nw/wsj/09/wsj_0932   0   17         4.1      CD               *)        -    -   -   -            *)           *        *           *   -
nw/wsj/09/wsj_0932   0   18        units    NNS               *)        -    -   -   -            *            *        *)          *   -
nw/wsj/09/wsj_0932   0   19      donated    VBN            (VP*     donate  01   1   -            *            *      (V*)          *   -
nw/wsj/09/wsj_0932   0   20           by     IN            (PP*         -    -   -   -            *            *   (ARG0*           *   -
nw/wsj/09/wsj_0932   0   21            a     DT         (NP(NP*         -    -   -   -            *            *        *           *   -
nw/wsj/09/wsj_0932   0   22      similar     JJ               *         -    -   -   -            *            *        *           *   -
nw/wsj/09/wsj_0932   0   23        group     NN               *)        -    -   -   -            *            *        *           *   -
nw/wsj/09/wsj_0932   0   24           of     IN            (PP*         -    -   -   -            *            *        *           *   -
nw/wsj/09/wsj_0932   0   25     surgical     JJ         (NP(NP*         -    -   -   -            *            *        *      (ARG0*   -
nw/wsj/09/wsj_0932   0   26     patients    NNS               *)        -    -   -   -            *            *        *           *)  -
nw/wsj/09/wsj_0932   0   27          who     WP     (SBAR(WHNP*)        -    -   -   -            *            *        *    (R-ARG0*)  -
nw/wsj/09/wsj_0932   0   28     received    VBD          (S(VP*    receive  01   -   -            *            *        *         (V*)  -
nw/wsj/09/wsj_0932   0   29            a     DT            (NP*         -    -   -   -            *            *        *      (ARG1*   -
nw/wsj/09/wsj_0932   0   30      placebo     NN               *         -    -   -   -            *            *        *           *   -
nw/wsj/09/wsj_0932   0   31    injection     NN   *)))))))))))))        -    -   -   -            *            *)       *)          *)  -
nw/wsj/09/wsj_0932   0   32            .      .              *))        -    -   -   -            *            *        *           *   -

nw/wsj/09/wsj_0932   0    0             The     DT  (TOP(S(S(NP(NP*           -    -   -   -           *        *       (ARG1*        *        *   -
nw/wsj/09/wsj_0932   0    1          volume     NN                *)          -    -   -   -           *        *            *        *        *   -
nw/wsj/09/wsj_0932   0    2              of     IN             (PP*           -    -   -   -           *        *            *        *        *   -
nw/wsj/09/wsj_0932   0    3             red     JJ          (NP(NP*           -    -   -   -           *   (ARG1*            *        *        *   -
nw/wsj/09/wsj_0932   0    4           cells    NNS                *)          -    -   -   -           *        *)           *        *        *   -
nw/wsj/09/wsj_0932   0    5         donated    VBN             (VP*       donate  01   1   -           *      (V*)           *        *        *   -
nw/wsj/09/wsj_0932   0    6              by     IN             (PP*           -    -   -   -           *   (ARG0*            *        *        *   -
nw/wsj/09/wsj_0932   0    7             the     DT             (NP*           -    -   -   -           *        *            *        *        *   -
nw/wsj/09/wsj_0932   0    8             EPO    NNP           (ADJP*           -    -   -   -           *        *            *        *        *   -
nw/wsj/09/wsj_0932   0    9              -    HYPH                *           -    -   -   -           *        *            *        *        *   -
nw/wsj/09/wsj_0932   0   10         treated    VBN                *)          -    -   -   -           *        *            *        *        *   -
nw/wsj/09/wsj_0932   0   11        patients    NNS           *))))))          -    -   -   -           *        *)           *)       *        *   -
nw/wsj/09/wsj_0932   0   12             was    VBD             (VP*           be  01   -   -           *        *          (V*)       *        *   -
nw/wsj/09/wsj_0932   0   13             41      CD        (ADVP(NP*           -    -   -   -   (PERCENT*        *       (ARG2*        *        *   -
nw/wsj/09/wsj_0932   0   14               %     NN                *)          -    -   -   -           *)       *            *        *        *   -
nw/wsj/09/wsj_0932   0   15          higher    JJR                *)          -    -   -   -           *        *            *)       *        *   -
nw/wsj/09/wsj_0932   0   16             per     IN             (PP*           -    -   -   -           *        *   (ARGM-PRD*        *        *   -
nw/wsj/09/wsj_0932   0   17           donor     NN          (NP*))))          -    -   -   -           *        *            *)       *        *   -
nw/wsj/09/wsj_0932   0   18               ,      ,                *           -    -   -   -           *        *            *        *        *   -
nw/wsj/09/wsj_0932   0   19             the     DT          (NP(NP*           -    -   -   -           *        *            *   (ARG0*   (ARG0*   -
nw/wsj/09/wsj_0932   0   20        research     NN                *           -    -   -   -           *        *            *        *        *   -
nw/wsj/09/wsj_0932   0   21            team     NN                *)          -    -   -   -           *        *            *        *)       *   -
nw/wsj/09/wsj_0932   0   22    representing    VBG             (VP*    represent  01   -   -           *        *            *      (V*)       *   -
nw/wsj/09/wsj_0932   0   23               a     DT          (NP(NP*           -    -   -   -           *        *            *   (ARG1*        *   -
nw/wsj/09/wsj_0932   0   24          number     NN                *)          -    -   -   -           *        *            *        *        *   -
nw/wsj/09/wsj_0932   0   25              of     IN             (PP*           -    -   -   -           *        *            *        *        *   -
nw/wsj/09/wsj_0932   0   26       hospitals    NNS          (NP(NP*)          -    -   -   -           *        *            *        *        *   -
nw/wsj/09/wsj_0932   0   27             and     CC                *           -    -   -   -           *        *            *        *        *   -
nw/wsj/09/wsj_0932   0   28           blood     NN             (NP*           -    -   -   -           *        *            *        *        *   -
nw/wsj/09/wsj_0932   0   29           banks    NNS           *))))))          -    -   -   -           *        *            *        *)       *)  -
nw/wsj/09/wsj_0932   0   30        reported    VBD             (VP*)      report  01   -   -           *        *            *        *      (V*)  -
nw/wsj/09/wsj_0932   0   31               .      .               *))          -    -   -   -           *        *            *        *        *   -

#end document
